Skip to main content
Consun Pharmaceutical Group Limited logo

Consun Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1681 HKEX Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2025-11-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1681

About Consun Pharmaceutical Group Limited

http://www.chinaconsun.com

Consun Pharmaceutical Group Limited is a modern pharmaceutical enterprise engaged in the integrated research, development, manufacturing, and marketing of pharmaceutical products. The company's core business is segmented into Modern Chinese Medicines (MCM) and Medical Contrast Medium products. The MCM portfolio targets major therapeutic areas, including chronic renal diseases (featuring products like Uremic Clearance Granules), liver and gallbladder conditions, and orthopedic trauma. In the medical imaging field, Consun supplies contrast agents such as Gadopentetate Dimeglumine Injection for magnetic resonance imaging (MRI) and Iopamidol Injection for angiography and neuro-radiology. The enterprise focuses on combining the modernization of Chinese medicine with advanced diagnostic solutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a standard monthly return (Form FF301) filed with the Hong Kong Exchange under Chapter 19B Listing Rules, detailing movements in share capital, issued shares, options, and treasury shares. It is a regulatory compliance filing rather than an earnings release, annual report, management discussion, proxy statement, or capital raising announcement. It does not fall under any specific transaction category like M&A or director dealings; it is a routine regulatory submission. Therefore it best fits the fallback category for general regulatory filings.
2025-11-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares, treasury share sales, and extensive share repurchases by the issuer. It is a mandatory regulatory report of the company buying back its own shares. This matches the definition of “Transaction in Own Shares” (Code: POS).
2025-10-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (form FF305) detailing changes in issued shares and treasury shares, specifically listing a series of repurchases of the company’s own shares, including dates, volumes, prices, aggregate amount, and confirmation of compliance with listing rules. This matches the definition of “Transaction in Own Shares (POS)” which covers reports of share buybacks or sales of treasury shares by the company. It is not a general share issuance notice (SHA) nor a report publication announcement (RPA), but the actual report of transactions in the issuer’s own shares.
2025-10-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) under Hong Kong Listing Rules detailing changes in issued shares and treasury shares, specifically outlining multiple share repurchases for cancellation, a repurchase report in Section II, and confirming compliance with listing rules. This is a direct report of the company buying back its own shares. It is not an announcement of an upcoming report or a summary but the actual repurchase transaction report. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2025-10-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a statutory “Next Day Disclosure Return” filed under Hong Kong Main Board/GEM Rules detailing repurchases of the company’s own shares, changes in issued shares and treasury shares, and confirmation that the share buybacks complied with listing rules. This is precisely a report of transactions in the company’s own shares (share repurchases), matching the “Transaction in Own Shares” category (POS).
2025-10-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a ‘Next Day Disclosure Return’ (Form FF305) under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares, treasury shares, and on-market repurchases of its own shares by Consun Pharmaceutical Group. It provides specific transaction data (dates, share counts, prices) for share buybacks and treasury share transfers, fitting the definition of a ‘Transaction in Own Shares’ report. This is not merely a notice of publication or dividend, nor a broader annual/interim report. Therefore, it should be classified as POS (Transaction in Own Shares).
2025-10-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.